@laurencelefou's Top Picks for 2023:@laurencelefou highlights one potential deal with a pharma or nutrition company as a catalyst for 2023. I assume he is refering to a PGX deal. Beyond a PGX deal additional catalysts for 2023:
1) Successful scale-up of PGX helping to de-risk the potential 40 million dose $100 million NPV plant for PGX-YBG.PGX-YBG has proven multi-fold more immuno-stimulatory than competitors which could make it the gold standard in the billion dollar YBG market.
2) Dr. Kolb and Dr. Ask helped Avalyn Pharma with its inhaled Pirfenidone. It raised C$80 million preclinically before the emergence of COVID. CZO's PGX-YBG may not only work with another drug like Pirfenidone or Nintedanib but as a standalone. It may also work beyond the lungs. PGX-YBG is now in studies that may pave the way for a Phase I trial shorlty for COVID. Inhaled PGX-YBG could also be used to deliver other drugs as Gilles has noted.
3) Concerning CZO's avenanthramide pill recently cleared for human clinical trials CZO's CEO stated it, "...
could be the most significant transformational step we have taken to date in executing on our strategy to expand Ceapro’s business model towards becoming a biopharmaceutical company with the potential to provide an innovative product into very large markets". Given the historical safety of avenanthramides the chief risk may largely and only be efficacy and this Phase 1/IIa trial will include patients with mild inflammation. It could provide hints of efficacy de-risking efficacy in very large markets.There is already signfiicant biomarker data for what is needed concerning cardiovascular disease. CZO's potent pill seeks to extend a trend already established in a previous human study using higher dosing and various dosing strategies. -----------------
@laurencelefou In order to have a shot at winning the contest, the three top picks must hit a Home Run or a Grand Slam and the ball must stay in the air until the end of the contest. In trying to hit a Home Run, the hitter might strike out. My picks for the 2023 CEO.CA #stockpickingcontest are: $RET $IPA $CZO. In alphabetical order :
1) Ceapro (CZO) The market cap is ±$50,757,000, the company has no debt and has $12,910,000 in cash. The trailing twelve months revenue is $19,080,000 and the TTM operating cash flow is $6,317,000. The operating business is very profitable and will finance the pharmaceutical and nutraceutical research projects that are ongoing. This year, Ceapro might partner or sign a licensing agreement with one pharmaceutical or nutritional company if this happens, investors should push the share price higher.
2) Immunoprecise Antibodies (IPA) The market cap is US$129,000,000, the company has no debt and has US$15,000,000 in cash. The trailing twelve months revenue is US$19,927,000 and the TTM operating cash flow saw an outflow of US$21,000,000. Only ±25,000,000 shares outstanding. If IPA signs one or more bio buck deals, if Biostrand research capabilities can generate revenues, and if one or many antibody candidates comes to market all of these events should push the share price higher.
3) Reitmans (RET.A). The market cap is ±$115,000,000, no debt and $64,000,000 in cash. Nine-month Revenue was $794,000,000 and operating cash flow was $96,816,000. The Reitmans family controls ±56% of the voting shares. If the Reitmans family decides to pay themselves and shareholders a dividend, the share price should move higher. It is prefereable to buy RET.A over RET.